---
title: "Comprehensive Patient Safety Protocols for Ketamine Clinics"
slug: "patient-safety-protocols-comprehensive"
excerpt: "An essential guide to developing and implementing robust patient safety protocols for ketamine clinics, including pre-treatment checklists, monitoring standards, emergency response procedures, and comprehensive documentation requirements."
category: "PRACTICE_MANAGEMENT"
author: "Ketamine Association Editorial Team"
publishedAt: "2026-01-08"
featuredImage: "/images/articles/placeholder.jpg"
tags: ["practitioners", "ketamine", "safety", "protocols", "emergency", "monitoring"]
audience: "practitioners"
---

# Comprehensive Patient Safety Protocols for Ketamine Clinics

Patient safety is the cornerstone of ethical and effective ketamine therapy. While ketamine has an excellent safety profile when administered appropriately, the dissociative and cardiovascular effects require systematic monitoring and prepared emergency response. This guide provides comprehensive safety protocols that every ketamine clinic should implement and regularly review.

## Foundations of Ketamine Safety

### Understanding Ketamine's Safety Profile

Ketamine's safety record stems from decades of anesthetic use, but therapeutic applications require adapted safety frameworks:

**Favorable Safety Characteristics**:
- Maintains airway reflexes at subanesthetic doses
- Minimal respiratory depression at therapeutic doses
- Wide therapeutic window
- Predictable onset and duration
- No specific reversal agent needed (effects are self-limiting)

**Safety Concerns Requiring Monitoring**:
- Cardiovascular stimulation (BP, HR elevation)
- Dissociation and altered consciousness
- Nausea and vomiting
- Transient psychotomimetic effects
- Abuse potential
- Potential for falls/injury during altered state

### Creating a Safety Culture

Safety protocols are only effective when embedded in practice culture:

**Safety Culture Elements**:
- Leadership commitment to safety
- Staff empowerment to raise concerns
- Non-punitive error reporting
- Regular safety training
- Continuous improvement mindset
- Patient partnership in safety

## Pre-Treatment Safety Checklist

### Day-Before Confirmation

**Patient Contact Points**:
- [ ] Confirm appointment date/time
- [ ] Review pre-treatment instructions
- [ ] Verify transportation arranged
- [ ] Confirm fasting instructions (if applicable)
- [ ] Address any patient questions
- [ ] Screen for intercurrent illness

### Pre-Treatment Instructions

**Standard Pre-Treatment Instructions**:

| Instruction | Timing | Rationale |
|-------------|--------|-----------|
| Arrange driver | Treatment day | Cannot drive after ketamine |
| Light meal | 4-6 hours before | Reduce nausea risk |
| Clear liquids | 2 hours before | Hydration, minimize aspiration risk |
| Take regular medications | Morning of | Unless instructed otherwise |
| Wear comfortable clothing | Treatment day | Comfort during treatment |
| Arrive 15-30 min early | Treatment day | Allow preparation time |
| Bring insurance/ID | Treatment day | Administrative requirements |

**Medication-Specific Instructions**:

| Medication | Instruction | Rationale |
|------------|-------------|-----------|
| Benzodiazepines | Hold on treatment day | May blunt ketamine effect |
| Lamotrigine | Take as usual | No significant interaction |
| MAOIs | Contraindicated | Safety concern |
| Stimulants | Hold morning dose | Cardiovascular concerns |
| Blood pressure medications | Take as usual | Cardiovascular safety |
| Diabetes medications | Special instructions | Blood sugar management |

### Day-of-Treatment Checklist

**Administrative Verification**:
- [ ] Patient identity confirmed
- [ ] Consent form signed and current
- [ ] Treatment plan reviewed
- [ ] Allergies verified
- [ ] Emergency contact information current

**Clinical Verification**:
- [ ] No new contraindications since evaluation
- [ ] No acute illness symptoms
- [ ] Fasting instructions followed
- [ ] Medications taken/held as instructed
- [ ] Driver present or confirmed
- [ ] Patient voided (emptied bladder)

**Pre-Treatment Assessment**:

| Assessment | Acceptable Range | Action if Abnormal |
|------------|-----------------|-------------------|
| Blood pressure | SBP <160, DBP <100 | Recheck; consider holding if elevated |
| Heart rate | 50-100 bpm | Investigate bradycardia/tachycardia |
| Oxygen saturation | ≥95% | Investigate if low |
| Mental status | Alert, oriented | Assess for intoxication, decompensation |
| Suicidal ideation | Assess with C-SSRS | Safety planning; consider alternatives |
| Pregnancy test | Negative (premenopausal) | Postpone if positive |

### Contraindication Re-Screening

Before each treatment, confirm absence of:

**Absolute Contraindications**:
- [ ] Uncontrolled hypertension (SBP >180 or DBP >110)
- [ ] Current psychotic symptoms
- [ ] Current manic episode
- [ ] Known pregnancy
- [ ] Acute intoxication
- [ ] Allergic reaction to ketamine
- [ ] Patient refusal/withdrawal of consent

**Relative Contraindications** (require clinical judgment):
- [ ] Recent substance use
- [ ] Elevated but controlled blood pressure
- [ ] Active infection/illness
- [ ] Significant anxiety about treatment
- [ ] Changes in medications
- [ ] Recent trauma or destabilizing events

## Monitoring During Treatment

### Monitoring Standards by Route

**IV Infusion Monitoring**:

| Parameter | Frequency | Documentation |
|-----------|-----------|---------------|
| Blood pressure | Every 10-15 minutes | Record each reading |
| Heart rate | Every 10-15 minutes | Record each reading |
| Oxygen saturation | Continuous or every 15 minutes | Record each reading |
| Respiratory rate | Every 15 minutes | Record each reading |
| Level of consciousness | Continuous observation | Document changes |
| Dissociation level | Peak and resolution | Document rating |

**IM Administration Monitoring**:

| Parameter | Frequency | Documentation |
|-----------|-----------|---------------|
| Blood pressure | Every 10-15 minutes | Record each reading |
| Heart rate | Every 10-15 minutes | Record each reading |
| Oxygen saturation | Every 15 minutes | Record each reading |
| Level of consciousness | Continuous observation | Document changes |

**Intranasal (Spravato) Monitoring**:

| Parameter | Frequency | Documentation |
|-----------|-----------|---------------|
| Blood pressure | 40 min, 1 hr, 1.5 hr, 2 hr | REMS requirements |
| Heart rate | With BP measurements | Record each |
| Oxygen saturation | PRN | If respiratory concern |
| Sedation level | Before discharge | Document assessment |

### Vital Sign Action Thresholds

**Blood Pressure**:

| Reading | Action |
|---------|--------|
| SBP 160-179 | Recheck in 5 min; consider intervention if persistent |
| SBP ≥180 | Hold/slow infusion; consider antihypertensive |
| SBP <90 | Stop infusion; assess volume status; position change |
| DBP ≥110 | As above for SBP ≥180 |

**Heart Rate**:

| Reading | Action |
|---------|--------|
| HR 100-120 | Monitor closely; usually acceptable |
| HR >120 | Assess for distress; consider slowing infusion |
| HR <50 | Stop infusion; assess patient; prepare for intervention |

**Oxygen Saturation**:

| Reading | Action |
|---------|--------|
| 92-94% | Recheck; consider supplemental O2 |
| <92% | Stop infusion; supplemental O2; assess airway |
| <88% | Emergency response; airway management |

### Behavioral Monitoring

**Normal Expected Behaviors**:
- Calm, relaxed posture
- Closed or partially closed eyes
- Minimal voluntary movement
- Slow, regular breathing
- Neutral or peaceful facial expression
- Responds to name (may be delayed)

**Concerning Behaviors Requiring Assessment**:

| Behavior | Possible Cause | Response |
|----------|---------------|----------|
| Severe agitation | Paradoxical reaction, anxiety | Verbal reassurance; consider benzodiazepine |
| Attempting to stand | Disorientation | Safety positioning; verbal redirection |
| Removing IV | Agitation, confusion | Verbal reassurance; assess IV integrity |
| Severe distress/crying | Psychological reaction | Supportive presence; assess for intervention |
| Vomiting | Nausea | Position safely; antiemetic; pause infusion |
| Unresponsive | Over-sedation | Assess airway; stimulate; prepare emergency response |

### Monitoring Equipment Maintenance

**Daily Checks**:
- [ ] Blood pressure cuff functioning
- [ ] Pulse oximeter reading accurately
- [ ] IV pump operational
- [ ] Oxygen supply adequate
- [ ] Suction operational
- [ ] Emergency equipment accessible

**Regular Maintenance**:

| Equipment | Maintenance | Frequency |
|-----------|-------------|-----------|
| BP monitor | Calibration check | Monthly |
| Pulse oximeter | Accuracy verification | Monthly |
| IV pumps | Biomedical inspection | Per manufacturer |
| AED | Battery/pad check | Monthly |
| Oxygen tanks | Quantity check | Daily |
| Crash cart | Contents inventory | Weekly |

## Emergency Response Procedures

### Medical Emergencies

**Hypertensive Emergency**:

*Definition*: SBP >180 and/or DBP >120 with evidence of end-organ damage

*Response Protocol*:
1. Stop ketamine infusion immediately
2. Maintain IV access
3. Assess neurological status (stroke symptoms)
4. Administer antihypertensive:
   - Labetalol 10-20 mg IV (if available and trained)
   - Or sublingual nifedipine 10 mg (avoid in acute MI)
5. Recheck BP every 5 minutes
6. If not responding or end-organ symptoms, activate EMS
7. Document timeline and interventions

**Respiratory Depression**:

*Definition*: SpO2 <90%, RR <8, or signs of airway obstruction

*Response Protocol*:
1. Stop ketamine infusion
2. Stimulate patient verbally and physically
3. Position airway (head tilt, chin lift, jaw thrust)
4. Apply supplemental oxygen (non-rebreather 15L/min)
5. If obstruction, use airway adjuncts (oral/nasal airway)
6. Prepare bag-valve mask if needed
7. If not improving, activate EMS
8. Document SpO2 trend and interventions

**Cardiac Arrest**:

*Response Protocol*:
1. Confirm unresponsiveness
2. Call for help / activate EMS (911)
3. Begin CPR immediately
4. Retrieve AED and apply
5. Follow AED prompts
6. Continue CPR until EMS arrival
7. Assign roles (CPR, AED, meet EMS)
8. Prepare handoff information for EMS

**Anaphylaxis**:

*Signs*: Urticaria, angioedema, bronchospasm, hypotension

*Response Protocol*:
1. Stop ketamine infusion
2. Call for help / consider EMS activation
3. Epinephrine 0.3-0.5 mg IM (thigh)
4. Position supine with legs elevated (if tolerated)
5. Supplemental oxygen
6. IV fluid bolus
7. Monitor airway closely
8. Repeat epinephrine every 5-15 minutes if needed
9. Transfer to emergency department

### Psychiatric Emergencies

**Severe Anxiety/Panic**:

*Response Protocol*:
1. Do NOT stop infusion immediately unless severe
2. Calm, reassuring verbal intervention
3. Grounding techniques
4. May slow infusion rate
5. If severe and non-responsive to verbal: midazolam 1-2 mg IV/IM
6. Document intervention and response
7. Consider protocol modification for future

**Emergence Delirium/Agitation**:

*Response Protocol*:
1. Ensure patient safety (prevent falls, injury)
2. Calm, repeated orientation statements
3. Low stimulation environment
4. If severe: midazolam 2-5 mg IM (or 1-2 mg IV)
5. Maintain monitoring until resolved
6. Do not discharge until fully oriented
7. Document thoroughly

**Acute Psychotic Symptoms**:

*Response Protocol*:
1. Stop ketamine infusion
2. Calm, non-threatening approach
3. Maintain safety of patient and staff
4. If severe: midazolam or haloperidol
5. Continuous monitoring
6. Psychiatric evaluation before discharge
7. Consider ketamine contraindication for future
8. Detailed documentation

**Suicidal Crisis**:

*Response Protocol*:
1. Assess immediacy and severity
2. Do not leave patient unattended
3. Remove potential means of harm
4. Engage in safety planning
5. Involve psychiatric support
6. Determine appropriate level of care
7. May require emergency psychiatric evaluation
8. Document risk assessment and plan

### Emergency Equipment Location and Use

**Emergency Equipment Checklist**:

Every treatment room should have immediate access to:
- [ ] Oxygen and delivery devices
- [ ] Suction equipment
- [ ] Bag-valve mask (Ambu bag)
- [ ] Oral and nasal airways
- [ ] AED
- [ ] Emergency medication kit

**Central Emergency Supply**:

| Item | Purpose | Location |
|------|---------|----------|
| Crash cart | Full emergency response | Central area |
| Emergency medications | Pharmacological intervention | Crash cart |
| Advanced airways | Airway management | Crash cart |
| Defibrillator/AED | Cardiac emergency | Central area |
| Backboard | CPR, transport | Accessible |

**Emergency Medications**:

| Medication | Indication | Dose | Route |
|------------|------------|------|-------|
| Epinephrine | Anaphylaxis, cardiac arrest | 0.3-0.5 mg | IM (1 mg IV for arrest) |
| Midazolam | Agitation, seizure | 1-5 mg | IV/IM |
| Labetalol | Hypertensive emergency | 10-20 mg | IV |
| Ondansetron | Nausea/vomiting | 4 mg | IV/ODT |
| Diphenhydramine | Allergic reaction | 25-50 mg | IV/PO |
| Naloxone | Opioid reversal (if co-administered) | 0.4-2 mg | IV/IM/IN |
| Atropine | Bradycardia | 0.5-1 mg | IV |
| Flumazenil | BZD reversal (rarely needed) | 0.2 mg | IV |

### Emergency Drills

**Drill Requirements**:

| Drill Type | Frequency | Participants | Documentation |
|------------|-----------|--------------|---------------|
| Cardiac arrest | Quarterly | All clinical staff | Date, participants, findings |
| Anaphylaxis | Quarterly | All clinical staff | Date, participants, findings |
| Respiratory emergency | Quarterly | All clinical staff | Date, participants, findings |
| Psychiatric emergency | Semi-annually | All clinical staff | Date, participants, findings |
| Full facility evacuation | Annually | All staff | Date, participants, findings |

**Drill Evaluation Elements**:
- Response time to recognition
- Appropriate initial actions
- Team communication
- Equipment accessibility and function
- Protocol adherence
- Areas for improvement

## Documentation Requirements

### Pre-Treatment Documentation

**Required Elements**:

| Document | Content | Timing |
|----------|---------|--------|
| Initial evaluation | Diagnosis, treatment plan, rationale | Before first treatment |
| Medical clearance | Physical exam, labs, contraindication screen | Before first treatment |
| Informed consent | Signed consent form | Before first treatment (renewed annually or with changes) |
| Pre-treatment checklist | Day-of verification | Each treatment |

### Treatment Session Documentation

**Minimum Documentation for Each Session**:

```
Date: _______________
Patient: _______________
Provider: _______________

Pre-Treatment:
- Vital signs: BP ____, HR ____, SpO2 ____, RR ____
- Mental status: _______________
- Contraindication screen: Clear / Concern noted: _______
- Fasting confirmed: Y / N
- Driver present: Y / N
- Consent verified: Y / N

Treatment:
- Route: IV / IM / IN / SL
- Dose: _____ mg (_____ mg/kg)
- Start time: _____
- End time: _____
- Total duration: _____

Monitoring (every 15 min):
Time | BP | HR | SpO2 | RR | Notes
____ | __ | __ | ____ | __ | _____
____ | __ | __ | ____ | __ | _____
____ | __ | __ | ____ | __ | _____
____ | __ | __ | ____ | __ | _____

Peak dissociation level (0-10): _____

Adverse Events: None / Described: ______________
Interventions: None / Described: ______________

Post-Treatment:
- Vital signs: BP ____, HR ____, SpO2 ____
- Mental status: _______________
- Ambulation test: Pass / Assist needed
- Discharge criteria met: Y / N
- Discharged with: _______________
- Post-treatment instructions given: Y / N

Provider signature: _______________
```

### Adverse Event Documentation

**Adverse Event Report Template**:

```
Date of Event: _______________
Patient: _______________
Provider: _______________

Event Description:
- Time of onset: _____
- Treatment phase (pre/during/post): _____
- Description: _______________________________________________
- Severity: Mild / Moderate / Severe
- Duration: _____

Vital Signs at Event:
BP: _____ HR: _____ SpO2: _____ RR: _____

Interventions:
1. _______________________________________________
2. _______________________________________________
3. _______________________________________________

Response to Interventions: _______________________________________________

Outcome:
- Resolved during session: Y / N
- Required additional care: Y / N
- EMS activated: Y / N
- Hospitalization: Y / N

Follow-up Required: Y / N
Follow-up Plan: _______________________________________________

Root Cause Analysis:
- Contributing factors: _______________________________________________
- Preventable: Y / N / Unknown
- Protocol changes needed: _______________________________________________

Reported to:
- [ ] Medical Director
- [ ] Quality Committee
- [ ] State/Federal as required
- [ ] Insurance as required

Provider Signature: _______________
Date: _______________
```

### Discharge Documentation

**Discharge Criteria Checklist**:
- [ ] Vital signs within acceptable range
- [ ] Mental status returned to baseline
- [ ] Ambulation without assistance
- [ ] No ongoing adverse effects requiring monitoring
- [ ] Understands post-treatment instructions
- [ ] Responsible adult present for transport
- [ ] Emergency contact information provided
- [ ] Follow-up appointment scheduled or discussed

**Post-Treatment Instructions** (provided in writing):

```
POST-KETAMINE TREATMENT INSTRUCTIONS

You received ketamine treatment today. Please follow these instructions:

IMMEDIATELY:
- Do NOT drive for 24 hours
- Do NOT operate heavy machinery
- Do NOT make important legal or financial decisions today
- Do NOT drink alcohol today

NORMAL EXPERIENCES (may occur for 24-48 hours):
- Mild dizziness or unsteadiness
- Fatigue or drowsiness
- Mild headache
- Unusual dreams
- Mild nausea

CALL US IF YOU EXPERIENCE:
- Severe or persistent headache
- Chest pain or difficulty breathing
- Severe nausea or vomiting
- Persistent confusion or disorientation
- Return of suicidal thoughts
- Any concerning symptoms

EMERGENCY:
Call 911 for any life-threatening emergency

CONTACT INFORMATION:
Clinic: _______________
After-hours: _______________

NEXT APPOINTMENT: _______________
```

## Post-Treatment Safety

### Recovery Assessment

**Recovery Milestones**:

| Assessment | Criteria | Timing |
|------------|----------|--------|
| Vital signs stable | Within 20% of baseline | Before discharge |
| Orientation | Person, place, time, situation | Before discharge |
| Ambulation | Can walk unassisted | Before discharge |
| Coordination | No significant ataxia | Before discharge |
| Cognition | Can follow instructions | Before discharge |
| Distress level | Manageable, not in crisis | Before discharge |

**Standardized Discharge Assessment**:

Modified Aldrete Score (adapted for ketamine):

| Parameter | Score 2 | Score 1 | Score 0 |
|-----------|---------|---------|---------|
| Activity | Moves all extremities | Moves 2 extremities | Unable to move |
| Respiration | Deep breath, cough | Dyspnea, shallow | Apneic |
| Circulation | BP ±20% of baseline | BP ±20-50% of baseline | BP >50% from baseline |
| Consciousness | Fully awake | Arousable | Not responding |
| SpO2 | >92% on room air | Needs O2 for >90% | <90% despite O2 |

**Discharge Requirement**: Score ≥8 (modified) with no individual parameter at 0

### Follow-Up Protocols

**24-48 Hour Follow-Up**:
- Phone or secure message check-in
- Assess for delayed adverse effects
- Evaluate initial treatment response
- Answer questions
- Document contact

**Ongoing Safety Monitoring**:
- Monitor for abuse/diversion indicators
- Track response and tolerance
- Assess for emerging contraindications
- Regular comprehensive reassessment

## Quality Improvement

### Safety Metrics Tracking

**Key Safety Metrics**:

| Metric | Target | Frequency |
|--------|--------|-----------|
| Adverse event rate | <5% | Monthly |
| Serious adverse event rate | <0.5% | Monthly |
| Emergency transfers | <0.1% | Monthly |
| Protocol deviation rate | <2% | Monthly |
| Patient complaints | Trending down | Monthly |
| Near-miss reports | Reviewed 100% | Weekly |

### Incident Review Process

**All Adverse Events**:
1. Immediate documentation
2. Staff debrief (same day)
3. Medical director review (within 24 hours)
4. Root cause analysis (within 1 week for serious events)
5. Protocol revision if indicated
6. Staff education if indicated
7. Follow-up with patient

**Serious Adverse Events**:
Additional steps:
- Peer review committee
- Risk management notification
- Regulatory reporting if required
- Insurance notification if required
- Legal review if indicated

### Continuous Improvement Cycle

```
Monitor → Identify Issues → Analyze Root Causes →
Develop Solutions → Implement Changes → Monitor (repeat)
```

**Regular Safety Reviews**:
- Weekly: Adverse event review
- Monthly: Safety metrics dashboard
- Quarterly: Protocol review
- Annually: Comprehensive safety audit

## Clinical Takeaways

1. **Systematic Checklists Prevent Errors**: Implement and rigorously use pre-treatment checklists to catch contraindications and ensure readiness before every treatment.

2. **Monitor According to Protocol**: Vital sign monitoring at specified intervals is non-negotiable. Train staff to recognize and respond to abnormal values promptly.

3. **Prepare for Emergencies**: Have equipment, medications, and protocols ready before they're needed. Regular drills ensure readiness when seconds count.

4. **Document Thoroughly**: Complete documentation protects patients by ensuring continuity and protects practitioners by demonstrating appropriate care.

5. **Never Skip Discharge Criteria**: Patients must meet objective discharge criteria before leaving. No exceptions for convenience or schedule pressure.

6. **Create a Reporting Culture**: Near-misses and adverse events are learning opportunities. Foster reporting without punishment to identify system weaknesses.

7. **Continuous Improvement Is Ongoing**: Safety is not a destination but a journey. Regularly review metrics, protocols, and outcomes to identify improvement opportunities.

8. **Safety Is Everyone's Responsibility**: From front desk to medical director, every team member plays a role in patient safety. Train and empower all staff accordingly.

---

*Patient safety in ketamine therapy requires systematic protocols, trained staff, and a culture of continuous improvement. This guide provides a framework, but each practice must adapt these principles to their specific setting and patient population.*

## References

1. American Society of Anesthesiologists. Standards for Basic Anesthetic Monitoring. ASA. 2020.
2. Joint Commission. National Patient Safety Goals. 2024.
3. Andrade C. Ketamine for Depression, 5: Potential Pharmacokinetic and Pharmacodynamic Drug Interactions. J Clin Psychiatry. 2017;78(7):e858-e861.
4. Sanacora G, et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry. 2017;74(4):399-405.
5. Institute for Safe Medication Practices. ISMP List of High-Alert Medications. ISMP. 2024.
